Epizyme, Inc.
EPZMDelisted Aug 12, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001571498
Epizyme, Inc. was delisted on Aug 12, 2022; its insiders filed their last Form 4 on Aug 16, 2022; 94 institutions reported holding it in 13F filings for Q2 2022, worth $187.0M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 94
- Q2 2022, −24 vs. previous quarter
- 13F value
- $187.0M
- Reported value at the end of Q2 2022
- Superinvestors holding
- 0
- At the end of Q2 2022
Superinvestors holding EPZM, Q2 2022
No superinvestor reported holding EPZM at the end of Q2 2022.
Latest insider trades
Open-market purchases and sales by Epizyme, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2022 (view filing) | Apr 11 | 2 days | Kutok JefferyChief Scientific Officer | SSaleCommon Stock, par value $0.0001 | −2.74K | $0.90 | −$2.47K | −2.8%94.6K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Beaulieu JosephCorporate Controller | SSaleCommon Stock, par value $0.0001 | −222 | $1.50 | −$333 | −0.8%28.6K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Agarwal ShefaliSee Remarks | SSaleCommon Stock, par value $0.0001 | −1.06K | $1.50 | −$1.59K | −0.7%156.4K after | |
| Feb 4, 2022 (view filing) | Feb 2 | 2 days | Agarwal ShefaliSee Remarks | SSaleCommon Stock, par value $0.0001 | −2.64K | $1.37 | −$3.62K | −1.6%157.4K after | |
| Feb 4, 2022 (view filing) | Feb 2 | 2 days | Kutok JefferyChief Scientific Officer | SSaleCommon Stock, par value $0.0001 | −2.56K | $1.37 | −$3.50K | −2.6%97.3K after | |
| Feb 4, 2022 (view filing) | Feb 2 | 2 days | Beaulieu JosephCorporate Controller | SSaleCommon Stock, par value $0.0001 | −687 | $1.37 | −$941.19 | −2.3%28.9K after | |
| Feb 1, 2022 (view filing)4:17 PM ET | Jan 31 | 1 day | Legorreta Pablo G. and 2 othersDirector, 10% Owner | PPurchase | +22.7M | $1.50 | +$34.0M | +247.3%31.8M after | |
| Jan 28, 2022 (view filing) | Jan 26 | 2 days | Agarwal ShefaliSee Remarks | SSaleCommon Stock, par value $0.0001 | −2.92K | $2.02 | −$5.90K | −1.8%160.1K after | |
| Dec 7, 2021 (view filing) | Dec 6 | 1 day | Agarwal ShefaliSee Remarks | SSaleCommon Stock, par value $0.0001 | −1.78K | $2.93 | −$5.22K | −1.1%163.0K after |
Top 10 13F holders, Q2 2022
The largest institutional positions in Epizyme, Inc. at the end of Q2 2022; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RP Management, LLC | 31,841,394 | $46.8M | 18.77% | +8,0600.0% | Added |
| Primecap Management Co | 16,642,727 | $24.5M | 0.02% | +1,119,950+7.2% | Added |
| Newtyn Management, LLC | 7,569,995 | $11.1M | 2.11% | +7,569,995 | New |
| Vanguard Group Inc | 7,540,469 | $11.1M | 0.00% | +90,313+1.2% | Added |
| Rock Springs Capital Management LP | 7,485,543 | $11.0M | 0.32% | +217,847+3.0% | Added |
| Palo Alto Investors LP | 6,774,541 | $9.96M | 0.87% | 00.0% | Unchanged |
| Platinum Investment Management Ltd | 6,603,870 | $9.71M | 0.37% | 00.0% | Unchanged |
| Rubric Capital Management LP | 6,283,690 | $9.24M | 0.49% | +6,283,690 | New |
| Woodline Partners LP | 3,866,148 | $5.68M | 0.09% | +2,366,148+157.7% | Added |
| BlackRock Inc. | 3,673,443 | $5.40M | 0.00% | −7,104,595−65.9% | Reduced |